Article

What level of neutralising antibody protects from COVID-19?

2021-03-11

Abstract excerpt

Both previous infection and vaccination have been shown to provide potent protection from COVID-19. However, there are concerns that waning immunity and viral variation may lead to a loss of protection over time. Predictive models of immune protection are urgently needed to identify immune correlates of protection to assist in the future deployment of vaccines. To address this, we modelled the relationship between...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 015036c4-22a3-579a-b209-c1e0c146b3c2
DOI: 10.1101/2021.03.09.21252641

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

What level of neutralising antibody protects from COVID-19?DOI 10.1101/2021.03.09.21252641Read

Neutralising antibodies predict protection from severe COVID-19Semantic proximity Read

SARS-CoV-2 variants: levels of neutralisation required for protective immunitySemantic proximity Read

Quantifying the role of naturally- and vaccine-derived neutralizing antibodies as a correlate of protection against COVID-19 variantsSemantic proximity Read

Breadth of neutralising antibody responses to SARS-CoV-2 variants of concern is augmented by vaccination following prior infection: studies in UK healthcare workers and immunodeficient patientsSemantic proximity Read

The Impact of SARS-CoV-2 Vaccination and Infection on Neutralising Antibodies: A Nation-Wide Cross-Sectional AnalysisSemantic proximity Read

COVID-19 herd immunity v. learning to live with the virus.Semantic proximity Read

Predicting COVID-19 Vaccine Efficacy from Neutralizing Antibody LevelsSemantic proximity Read

Previously infected vaccinees broadly neutralize SARS-CoV-2 variantsSemantic proximity Read

Kinetics of naturally induced binding and neutralising anti-SARS-CoV-2 antibody levels and potencies among SARS-CoV-2 infected Kenyans with diverse grades of COVID-19 severity: an observational studySemantic proximity Read

Persistence of immunity and impact of a third (booster) dose of an inactivated SARS-CoV-2 vaccine, BBV152; a phase 2, double-blind, randomised controlled trialSemantic proximity Read

Long term vaccination strategies to mitigate the impact of SARS-CoV-2 transmission: a modelling studySemantic proximity Read

Cellular Immune Responses are Preserved and May Contribute to Chadox1 ChAdOx1 nCoV-19 Vaccine Effectiveness Against Infection Due to SARS-CoV-2 B·1·617·2 Delta Variant Despite Reduced Virus NeutralisationSemantic proximity Read